Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171145 · ClinicalTrials.gov registry record · Phase 3
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
A Phase 3 study of Overactive Bladder Syndrome, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 445
- Enrollment target
- 1
- Study location
NCT00171145 is a Phase 3 study of Overactive Bladder Syndrome that has completed, run by Novartis. The registered enrollment target is 445 participants, above the 81-participant average among 11 other Overactive Bladder Syndrome trials with a reported enrollment target (449% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00171145, a Phase 3 study of Overactive Bladder Syndrome, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 445 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Darifenacin
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2004-04 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171145
The ClinicalTrials.gov registry entry for NCT00171145 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 445 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 81-participant average among 11 other Overactive Bladder Syndrome trials with a reported enrollment target (449% higher). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Overactive Bladder Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00171145 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00171145 about?
NCT00171145 is a clinical study titled "A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.". This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
What is the current status of trial NCT00171145?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2004-04. Estimated completion is 2004-12.
What conditions does trial NCT00171145 study?
This clinical trial studies the following conditions: Overactive Bladder Syndrome.
What interventions are being tested in trial NCT00171145?
The interventions under investigation include: Placebo (DRUG), Darifenacin (DRUG).
Who is sponsoring clinical trial NCT00171145?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00171145 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oxybutynin for Post-surgical Bladder Pain and Urgency
RECRUITING · Phase 3
-
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
COMPLETED · Phase 3
-
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
RECRUITING · Phase 2
-
Improving Overactive Bladder Treatment Access and Adherence
RECRUITING · NA
-
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
RECRUITING · Phase 2
-
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.